Explore how multi-angle light scattering enhances biosimilar analysis by delivering accurate molecular weight and size ...

Biosimilars (non-branded versions of large molecule originator medicines) have impacted the drug market in recent years increasing their market share as healthcare providers have opted for lower cost ...

For regulatory approval, biosimilar drugs must not have any clinically-meaningful differences compared to the approved medicines they are modeled after. To evaluate the safety, purity, and potency of ...

On paper, biosimilars have great potential to cut development costs, expand patient access to biologics, and improve affordability. The practical reality is that these goals are difficult to achieve.

A biosimilar is a biologic medication that is highly similar to an existing FDA-approved biologic, known as a reference product, with no clinically meaningful differences. Biosimilars are derived from ...

The Trump administration’s latest effort to lower drug costs is expanding to biosimilars, medications that are highly similar to biologic drugs made with or isolated from living organisms such as ...

The US Food and Drug Administration will take steps to streamline the development of generic versions of complex biological drugs, the agency announced Wednesday. The changes are meant to accelerate ...

Though biologic medications have improved the treatment landscape by providing the solution to many unmet medical needs, biologics cost much more than small-molecule chemical medications. Biosimilars ...

Forbes contributors publish independent expert analyses and insights. Ge Bai is professor of accounting & health policy at Johns Hopkins. Biologic drugs, made from living organisms and usually taken ...

Biosimilars are gaining traction as competitors aim to capture market share from branded biologics such as Humira and Neulasta. Humira now faces competition from seven biosimilars, while Neulasta has ...